PPGN POLYPEPTIDE GROUP AG

PolyPeptide secures revolving credit facility

PolyPeptide Group / Key word(s): Financing
PolyPeptide secures revolving credit facility

02.10.2023 / 07:00 CET/CEST


Media Release

PolyPeptide secures revolving credit facility

Baar, 2 October 2023 – PolyPeptide Group AG (SIX: PPGN) announces the signing of a revolving credit facility agreement with Credit Suisse, Danske Bank and Zürcher Kantonalbank as mandated lead arrangers, complemented by the extension of the credit facility with its majority shareholder, concluding the previously disclosed financing negotiations.

With Credit Suisse as the coordinator and agent, the banks committed to a three-year revolving credit facility (RCF) in the amount of EUR 111 million with an uncommitted increase option of EUR 40 million. The RCF allows PolyPeptide to refinance its existing borrowings from banks as well as finance its working capital and capital expenditure requirements to support its planned business growth.

In parallel, Draupnir Holding B.V. agreed to extend its EUR 40 million credit facility, which may be refinanced under the RCF subject to certain conditions. 

Lalit Ahluwalia, CFO of PolyPeptide, comments: «The financing gives us the flexibility to invest to meet the needs of our customers as we implement our turnaround plans. We remain focused on operational execution while managing costs and optimizing net working capital.»

 

 

Contact

Michael Stäheli
Head of Investor Relations & Corporate Communications

T:

About PolyPeptide

PolyPeptide Group AG with its consolidated subsidiaries (“PolyPeptide”) is a focused Contract Development & Manufacturing Organization (CDMO) for peptide- and oligonucleotide-based active pharmaceutical ingredients. By supporting its customers mainly in pharma and biotech, it contributes to the health of millions of patients across the world. PolyPeptide offers products and services from pre-clinical through to commercial stages, including generics. Its active custom projects pipeline reflects the opportunities from novel drug therapies in development to fight both widespread and rare diseases. Dating back to 1952, PolyPeptide today runs a global network of six cGMP-certified facilities in Europe, the U.S. and India. PolyPeptide’s shares (SIX: PPGN) are listed on SIX Swiss Exchange. For more information, please visit .

@PolyPeptide – follow us on

Disclaimer

This media release has been prepared by PolyPeptide Group AG and contains certain forward-looking statements that reflect the current views of management. Such statements are subject to known and unknown risks, uncertainties and other factors that may cause actual developments to differ materially from those expressed or implied in this release. PolyPeptide Group AG is providing the information in this release as of this date and, except as required by applicable laws or regulations, does not undertake any obligation to update any statements contained in it as a result of new information, future events or otherwise.


Additional features:

File:


End of Media Release


Language: English
Company: PolyPeptide Group
Neuhofstrasse 24
6340 Baar
Switzerland
Phone:
E-mail:
Internet:
ISIN: CH1110760852
Valor: 111076085
Listed: SIX Swiss Exchange
EQS News ID: 1738637

 
End of News EQS News Service

1738637  02.10.2023 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1738637&application_name=news&site_id=research_pool
EN
02/10/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on POLYPEPTIDE GROUP AG

 PRESS RELEASE

PolyPeptide gibt Ergebnisse der ordentlichen Generalversammlung 2025 b...

PolyPeptide Group / Schlagwort(e): Generalversammlung PolyPeptide gibt Ergebnisse der ordentlichen Generalversammlung 2025 bekannt 09.04.2025 / 18:34 CET/CEST Medienmitteilung PolyPeptide gibt Ergebnisse der ordentlichen Generalversammlung 2025 bekannt Baar, 9. April 2025 – PolyPeptide Group AG (SIX: PPGN), ein spezialisierter globaler CDMO für peptidbasierte pharmazeutische Wirkstoffe, gab heute bekannt, dass die Aktionärinnen und Aktionäre an der vierten ordentlichen Generalversammlung der Gesellschaft allen Anträgen des Verwaltungsrats mit grosser Mehrheit zugestimmt ha...

 PRESS RELEASE

PolyPeptide announces results of the annual General Meeting 2025

PolyPeptide Group / Key word(s): AGMEGM PolyPeptide announces results of the annual General Meeting 2025 09.04.2025 / 18:34 CET/CEST Media releasePolyPeptide announces results of the annual General Meeting 2025 Baar, 9 April 2025 – PolyPeptide Group AG (SIX: PPGN), a specialized global CDMO for peptide-based active pharmaceutical ingredients, today announced that the shareholders approved all proposals put forward by the Board of Directors at the Company’s fourth annual General Meeting with a large majority. The Chair of the Board of Directors of PolyPeptide Group AG (the ...

 PRESS RELEASE

PolyPeptide publiziert Einladung zur ordentlichen Generalversammlung 2...

PolyPeptide Group / Schlagwort(e): Generalversammlung PolyPeptide publiziert Einladung zur ordentlichen Generalversammlung 2025 18.03.2025 / 07:00 CET/CEST Medienmitteilung PolyPeptide publiziert Einladung zur ordentlichen Generalversammlung 2025 Baar, 18. März 2025 – PolyPeptide Group AG (SIX: PPGN), eine spezialisierte globale CDMO für peptidbasierte aktive pharmazeutische Wirkstoffe, hat heute die Einladung zur vierten ordentlichen Generalversammlung publiziert, die am 9. April 2025 in der Chollerhalle in Zug stattfinden wird. An PolyPeptide Group AG’s (die "Gesellsch...

 PRESS RELEASE

PolyPeptide publishes invitation to the annual General Meeting 2025

PolyPeptide Group / Key word(s): AGMEGM PolyPeptide publishes invitation to the annual General Meeting 2025 18.03.2025 / 07:00 CET/CEST Media release PolyPeptide publishes invitation to the annual General Meeting 2025 Baar, 18 March 2025 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide-based active pharmaceutical ingredients, published today the invitation to the fourth annual General Meeting, which will take place on 9 April 2025 at the Chollerhalle in Zug. At PolyPeptide Group AG’s (the “Company”) fourth annual General Meeting, which will take place...

 PRESS RELEASE

Doubling of production capacity at the manufacturing site in Malmö

PolyPeptide Group / Key word(s): Expansion Doubling of production capacity at the manufacturing site in Malmö 08.01.2025 / 07:00 CET/CEST Media release Doubling of production capacity at the manufacturing site in Malmö Baar, 8 January 2025 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide-based active pharmaceutical ingredients, announces the planned doubling of solid-phase peptide synthesis (SPPS) capacity at its manufacturing site in Malmö, Sweden. The construction work is already underway, along with the supporting infrastructure, including a tan...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch